Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
TOKYO (Reuters) - Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday.
The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.
Eisai already has a dementia drug on the U.S. market called Leqembi, co-developed with U.S. peer Biogen.
The companies announced on Friday that they would start Leqembi sales in China, making that country the third where the treatment is available after the U.S. and Japan.
(Reporting by Kevin Buckland; Editing by Christopher Cushing)
